A multicenter single‑arm Phase II clinical trial of second‑line FOLFIRI plus panitumumab after first‑line treatment with FOLFOX plus panitumumab for initial RAS wild‑type colorectal cancer with evaluation of circulating tumor DNA: A protocol study

Maeda,Hiromichi; Nagata,Naoki; Nagasaka,Takeshi; Oba,Koji; Mishima,Hideyuki; Kato,Takeshi; Yoshida,Kazuhiro; Muro,Kei; Sakamoto,Junichi

doi:10.3892/ol.2018.9763

A multicenter single‑arm Phase II clinical trial of second‑line FOLFIRI plus panitumumab after first‑line treatment with FOLFOX plus panitumumab for initial RAS wild‑type colorectal cancer with evaluation of circulating tumor DNA: A protocol study

Authors:
- Hiromichi Maeda
- Naoki Nagata
- Takeshi Nagasaka
- Koji Oba
- Hideyuki Mishima
- Takeshi Kato
- Kazuhiro Yoshida
- Kei Muro
- Junichi Sakamoto
View Affiliations

Affiliations: Cancer Treatment Center, Kochi Medical School Hospital, Kochi University, Nankoku, Kochi 783‑8505, Japan, Kitakyushu General Hospital, Kitakyushu, Fukuoka 802‑8517, Japan, Department of Gastroenterological Surgery Transplant and Surgical Oncology, Okayama University Graduate School of Medicine Dentistry and Pharmaceutical Sciences, Okayama 700‑8530, Japan, Department of Biostatistics, Graduate School of Medicine, The University of Tokyo, Tokyo 113‑8654, Japan, Cancer Center, Aichi Medical University, Nagakute, Aichi 480‑1195, Japan, Department of Surgery, National Hospital Organization Osaka National Hospital, Osaka, Osaka 540‑0006, Japan, Second Department of Surgery, Gifu University, Gifu, Gifu 501‑1194, Japan, Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Aichi 464‑8681, Japan, Tokai Central Hospital, Kakamigahara, Gifu 504‑8601, Japan
Published online on: November 27, 2018 https://doi.org/10.3892/ol.2018.9763
Pages: 1980-1985

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The efficacy and safety of the continuous use of panitumumab in first‑ and second‑line treatments for colorectal cancer (CRC) have yet to be determined. Liquid biopsy of circulating tumor DNA is capable of assessing the gene mutation status at several time‑points, and could predict the efficacy of ongoing panitumumab treatment. To address these two points, a multicenter single‑arm Phase II clinical trial will be conducted by evaluating the effect of FOLFIRI with panitumumab as second‑line chemotherapy in patients with CRC, after failure or intolerance of first‑line treatment with FOLFOX with panitumumab. The primary endpoint is the 6‑month progression‑free survival rate. Gene mutation status using circulating tumor DNA will be assessed at multiple time‑points during the study period as one of the secondary endpoints. The observed 6‑month PFS rate will be compared with the threshold 6‑month PFS rate of 35% with a one‑sided significance level of 10% using the binomial exact test. The target number of cases in this study is 55 patients. The study protocol was approved by the Institutional Review Board of the Epidemiological and Clinical Research Information Network (17‑0601‑1) and will be conducted after approval by the Institutional Review Board of each participating institute. This study is registered in UMIN (UMIN000026817, March 31, 2017). The results of the present study will be presented at related international congresses, and will be disseminated in peer‑reviewed journals.

View Figures

View References

1	Stintzing S, Modest DP, Rossius L, Lerch MM, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, et al: FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): A post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial. Lancet Oncol. 17:1426–1434. 2016. View Article : Google Scholar : PubMed/NCBI
2	Grothey A, Sargent D, Goldberg RM and Schmoll HJ: Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol. 22:1209–1214. 2004. View Article : Google Scholar : PubMed/NCBI
3	Bennouna J, Sastre J, Arnold D, Österlund P, Greil R, Van Cutsem E, von Moos R, Viéitez JM, Bouché O, Borg C, et al: Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): A randomised phase 3 trial. Lancet Oncol. 14:29–37. 2013. View Article : Google Scholar : PubMed/NCBI
4	Jonker DJ, O'Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au HJ, Berry SR, Krahn M, Price T, Simes RJ, et al: Cetuximab for the treatment of colorectal cancer. N Engl J Med. 357:2040–2048. 2007. View Article : Google Scholar : PubMed/NCBI
5	Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, et al: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 351:337–345. 2004. View Article : Google Scholar : PubMed/NCBI
6	Naruse I, Ohmori T, Ao Y, Fukumoto H, Kuroki T, Mori M, Saijo N and Nishio K: Antitumor activity of the selective epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) Iressa (ZD1839) in an EGFR-expressing multidrug-resistant cell line in vitro and in vivo. Int J Cancer. 98:310–315. 2002. View Article : Google Scholar : PubMed/NCBI
7	Sclabas GM, Fujioka S, Schmidt C, Fan Z, Evans DB and Chiao PJ: Restoring apoptosis in pancreatic cancer cells by targeting the nuclear factor-kappaB signaling pathway with the anti-epidermal growth factor antibody IMC-C225. J Gastrointest Surg. 7:37–43. 2003. View Article : Google Scholar : PubMed/NCBI
8	Huang SM and Harari PM: Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: Inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin Cancer Res. 6:2166–2174. 2000.PubMed/NCBI
9	Van Emburgh BO, Sartore-Bianchi A, Di Nicolantonio F, Siena S and Bardelli A: Acquired resistance to EGFR-targeted therapies in colorectal cancer. Mol Oncol. 8:1084–1094. 2014. View Article : Google Scholar : PubMed/NCBI
10	Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, Li M, Thornton K, Agrawal N, Sokoll L, Szabo SA, et al: Circulating mutant DNA to assess tumor dynamics. Nat Med. 14:985–990. 2008. View Article : Google Scholar : PubMed/NCBI
11	Diaz LA Jr, Williams RT, Wu J, Kinde I, Hecht JR, Berlin J, Allen B, Bozic I, Reiter JG, Nowak MA, et al: The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature. 486:537–540. 2012. View Article : Google Scholar : PubMed/NCBI
12	Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer Res. 45:228–247. 2009. View Article : Google Scholar
13	Nagasaka T, Tanaka N, Cullings HM, Sun DS, Sasamoto H, Uchida T, Koi M, Nishida N, Naomoto Y, Boland CR, et al: Analysis of fecal DNA methylation to detect gastrointestinal neoplasia. J Natl Cancer Inst. 101:1244–1258. 2009. View Article : Google Scholar : PubMed/NCBI
14	Peeters M, Oliner KS, Price TJ, Cervantes A, Sobrero AF, Ducreux M, Hotko Y, André T, Chan E, Lordick F, et al: Analysis of KRAS/NRAS mutations in a phase III study of panitumumab with FOLFIRI compared with FOLFIRI alone as second-line treatment for metastatic colorectal cancer. Clin Cancer Res. 21:5469–5479. 2015. View Article : Google Scholar : PubMed/NCBI
15	Sidhu R, Rong A and Dahlberg S: Evaluation of progression-free survival as a surrogate endpoint for survival in chemotherapy and targeted agent metastatic colorectal cancer trials. Clin Cancer Res. 19:969–976. 2013. View Article : Google Scholar : PubMed/NCBI
16	Shi Q, de Gramont A, Grothey A, Zalcberg J, Chibaudel B, Schmoll HJ, Seymour MT, Adams R, Saltz L, Goldberg RM, et al: Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials: Findings from the analysis and research in cancers of the digestive system database. J Clin Oncol. 33:22–28. 2015. View Article : Google Scholar : PubMed/NCBI